Starling Oncology, Inc. cash flow to debt ratio of -23.71% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Starling Oncology, Inc. has insufficient data to evaluate this check.

Starling Oncology, Inc. has insufficient data to evaluate this check.

Starling Oncology, Inc. has insufficient data to evaluate this check.

Starling Oncology, Inc. has negative EBITDA, making leverage ratio unreliable

Starling Oncology, Inc.'s interest coverage ratio is -6.28, which means that the company struggles to meet interest obligations, signaling financial risk.

Starling Oncology, Inc. has insufficient data to evaluate this check.

Starling Oncology, Inc. has insufficient data to evaluate this check.

Starling Oncology, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Starling Oncology, Inc.'s return on equity of 209.81%, is higher than 15.00%, indicating good performance

Starling Oncology, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Starling Oncology, Inc. has insufficient public price history to evaluate earnings stability.

Starling Oncology, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Starling Oncology, Inc. has negative free cash flow, indicating cash burn

Starling Oncology, Inc. has insufficient data to evaluate this check.

Starling Oncology, Inc. has insufficient data to evaluate this check.

ROIC -28.82% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Starling Oncology, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Starling Oncology, Inc. has insufficient public price history to evaluate revenue consistency.

Starling Oncology, Inc. has insufficient public price history to evaluate ROE consistency.

Starling Oncology, Inc. has insufficient data to evaluate this check.

Starling Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Starling Oncology, Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Starling Oncology, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Starling Oncology, Inc. has insufficient data to evaluate this check.

Starling Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Starling Oncology, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Starling Oncology, Inc. has a price-to-sales ratio of 1.20x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue